Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,138.2
-0.6 (-0.02%)

 

  • STI Straits Times Index
    3,138.2
    -0.6 (-0.02%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,513.6
    -1.0 (-0.07%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,249.3
    162.9 (0.65%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,317.6
    -63.6 (-1.88%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,749.6
    -220.6 (-0.79%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,097.0
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 239.3M
  • Value: 267.6M
  • Rise: 138
  • Fall: 76
  • Unch: 547

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
MM2 Asia0.071+0.004
Sembcorp Marine0.110+0.001
Metal Component0.059+0.002
Olam Intl1.280-0.060
Leader Env0.082+0.004
Golden Agri-Res0.210-
KTL Global^0.117-0.005
GSS Energy0.068+0.001
Singtel2.240+0.010
Mercurius0.064+0.002

World Indices

World Indices
Name Last Change
Nasdaq 14,660.6 -180.1
HSI 25,309.3 +222.8
HSCEI 9,016.7 +137.1
Jakarta 6,109.8 +12.7
Nikkei 225 27,667.8 -302.4
SSE Comp 3,353.4 -27.8
Shanghai A 3,514.6 -29.1
Shanghai B 254.9 -1.9
KOSPI 3,233.2 +0.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Phapros Tbk. PT PHAPROS TBK
Quotes 10 Minutes Delayed. No Trades for The Day
Last (IDR): 1,175.000 Change: - High: 1,175.000 Remarks: -
Change (%): - Low: 1,175.000
Open 1,175.000 Yesterday's Close 1175.000
Buy Price 1175.000 Sell Price 1185.000
Buy Volume ('000) 0.2 Sell Volume ('000) 0.1
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (IDR) a 57.72365 Trailing EPS (IDR) e 82.71207 NAV (IDR) b 865.2471
PE a 20.356 Trailing PE f 14.206 Price / NAV b 1.3580
Dividend (IDR) d 23.089464 Cash In Hand (IDR) g 85.4138 Issued & Paid-up Shares c 840,000,000
Dividend Yield (%) d 1.965 Price / Cash In Hand g 13.757 Treasury Shares h -
Beta - 75 Daysi -0.131 R-Squared - 75 Days(%)i 0.08 Market Cap (M) 987,000.000
Beta - 500 Daysi 1.130 R-Squared - 500 Days (%)i 11.37 Enterprise Value (M) 1,910,239.137
Piotroski F Score 4 Exchange Code PEHA Par Value ( IDR ) 100.00000
52 Weeks Volatility (%) 64.25 6-Month VWAP 1305.528 Free Float (%) 34.4
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 27 Dec 2018.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 27 Dec 2018.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Phapros Tbk. IDX 987,000.000 20.356 14.206 1.3580 1.965
Industry Pharmaceuticals: Major IDX 6,225,730.801 80.297 73.118 2.3171 1.528
Local Peer Kimia Farma Tbk. IDX 16,273,220.003 922.579 1,855.552 2.3183 0.043
Local Peer Soho Global Health Tbk. IDX 6,295,083.200 36.576 36.576 2.6955 4.758
Local Peer Merck Tbk. IDX 1,514,240.000 21.060 16.783 2.2736 3.609
Global Peer JOHNSON & JOHNSON NYSE 454,682.844 30.901 25.591 - 2.304
Global Peer PFIZER INC NYSE 235,662.749 24.507 21.248 3.4343 3.614
Global Peer ELI LILLY AND COMPANY NYSE 233,599.553 37.716 38.342 33.8616 1.212
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 222,311.234 27.378 24.717 4.1137 2.111
Global Peer ABBVIE INC NYSE 208,343.311 45.729 40.980 15.1965 4.101
Global Peer MERCK & CO INC NYSE 197,120.871 27.893 28.048 7.3157 3.183
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 178,024.296 55.272 44.456 12.3371 2.020
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 158,910.004 24.661 23.638 17.1905 1.501
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 150,767.936 - - 4.0092 2.739
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 130,113.012 9.269 9.269 1.6879 2.597
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), HANSOH PHARMA (HKEx), VIATRIS INC (NASDAQ), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), REPLIGEN CORP (NASDAQ), CUREVAC NV (NASDAQ), SINOPHARM (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), ORGANON & CO (NYSE), HUTCHMED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), SH PHARMA (HKEx), JUNSHI BIO (HKEx), HYGEIA HEALTH (HKEx), REMEGEN-B (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), CMS (HKEx), AKESO-B (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), INNOCARE-B (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), BAIYUNSHAN PH (HKEx), ALLAKOS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), CHINARES PHARMA (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), KARUNA THERAPEUTICS INC (NASDAQ), SIMCERE PHARMA (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), TRAD CHI MED (HKEx), NEKTAR THERAPEUTICS (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), CHINAGRANDPHARM (HKEx), IGM BIOSCIENCES INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), OPKO HEALTH INC (NASDAQ), CSTONE PHARMA-B (HKEx), EVEREST MED-B (HKEx), HENLIUS (HKEx), ERASCA INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CARSGEN-B (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP (HKEx), HEPALINK (HKEx), OCUMENSION-B (HKEx), ADC THERAPEUTICS SA (NYSE), ZYMEWORKS INC (NYSE), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), Y-MABS THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), UNITED LAB (HKEx), ANTENGENE-B (HKEx), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), REPARE THERAPEUTICS INC (NASDAQ), TONGRENTANGCM (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KRONOS BIO INC (NASDAQ), GENERATION BIO CO (NASDAQ), IMMUNOTECH-B (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), PETIQ INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), SCICLONE PHARMA (HKEx), CKLIFE SCIENCES (HKEx), PHIBRO ANIMAL HEALTH CORP (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), ANNOVIS BIO INC (NYSE American), KEROS THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), GH RESEARCH PLC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), SHINEWAY PHARM (HKEx), ANNEXON INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), ZHAOKE OPHTH-B (HKEx), EVOLUS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), AC IMMUNE SA (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), HUA MEDICINE-B (HKEx), TARSUS PHARMACEUTICALS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), CLENE INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), PHARVARIS NV (NASDAQ), INOZYME PHARMA INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), IGBB (Bursa), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), RACE ONCOLOGY LTD (ASX), STARPHARMA HOLDINGS LIMITED (ASX), PROVENTION BIO INC (NASDAQ), BEYONDSPRING INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), XOMA CORP (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), BIOMEA FUSION INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), ATHENEX INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), 89BIO INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), DAWNRAYS PHARMA (HKEx), THERATECHNOLOGIES INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), DURECT CORP (NASDAQ), BSTEAD (Bursa), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), GAMIDA CELL LTD (NASDAQ), TOT BIOPHARM-B (HKEx), VERRICA PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), VINCERX PHARMA INC (NASDAQ), PHARMA (Bursa), 180 LIFE SCIENCES CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), NEXIMMUNE INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), FUSEN PHARM (HKEx), IMMUNIC INC (NASDAQ), MUSTANG BIO INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), HARROW HEALTH INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), OBSEVA SA (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), IP (SET), LANNETT CO INC (NYSE), ONCTERNAL THERAPEUTICS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), CH BIOTECH SER (HKEx), PHASEBIO PHARMACEUTICALS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), LANTERN PHARMA INC (NASDAQ), IMARA INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), POLYPID LTD (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), ODONATE THERAPEUTICS INC (NASDAQ), ZHONGZHIPHARM (HKEx), RECCE PHARMACEUTICALS LTD (ASX), IX Biopharma (SGX), AQUESTIVE THERAPEUTICS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), NOVAN INC (NASDAQ), ENTERA BIO LTD (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), EYENOVIA INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), GALECTO INC (NASDAQ), PROPHASE LABS INC (NASDAQ), CRESO PHARMA LTD (ASX), MEDIWOUND LTD (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), NEW RAY MEDIC (HKEx), MOLECULIN BIOTECH INC (NASDAQ), CHARMACY PHAR (HKEx), GRAYBUG VISION INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), KOTRA (Bursa), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), PAK FAH YEOW (HKEx), NC HEALTHCARE (HKEx), Hyphens Pharma (SGX), EDESA BIOTECH INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), BIOHLDG (Bursa), NOVA (Bursa), MODERN CHI MED (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), EXOPHARM LTD (ASX), SYNAPTOGENIX INC (NASDAQ), MANNATECH INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), INVION LTD (ASX), NEP INTERLONG (HKEx), ASSERTIO HOLDINGS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), ACURX PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG (HKEx), VIRIOS THERAPEUTICS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), ADIAL PHARMACEUTICALS INC (NASDAQ), PALLA PHARMA LTD (ASX), TBG DIAGNOSTICS LTD (ASX), CNS PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), PURAPHARM (HKEx), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), SANAI HEALTH GP (HKEx), PANBELA THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), JCT (SET), VALLON PHARMACEUTICALS INC (NASDAQ), SUNZEN (Bursa), PHARMAXIS (ASX), AVENUE THERAPEUTICS INC (NASDAQ), EXTRAWELL PHAR (HKEx), PETROS PHARMACEUTICALS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), TALI DIGITAL LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), ACRUX (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), ISLAND PHARMACEUTICALS LTD (ASX), SINOLIFE UTD (HKEx), SUDA PHARMACEUTICALS LTD (ASX), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), CELLMID LIMITED (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --15.000
-1.26 %
10 Days --5.000
-0.42 %
20 Days --5.000
-0.42 %
Medium Term Return 3 Months 23.089-70.000
-3.77 %
6 Months 23.089-250.000
-15.92 %
1 Year 23.089-365.000
-22.20 %
Long Term Return 2 Years 13372.799-560.000
+738.49 %
Annualised Return Annualised --
+189.57 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 1,085.000 - 2,970.000 Change From 1 Year Low +90.000 % Change From 1 Year Low (%) +8.29
Change From 1 Year High -1795.000 % Change From 1 Year High (%) -60.44
2 Years Range 655.000 - 2,970.000 Change From 2 Years Low +520.000 % Change From 2 Years Low (%) +79.39
Change From 2 Years High -1795.000 % Change From 2 Years High (%) -60.44
5 Years Range 655.000 - 3,650.000 Change From 5 Years Low +520.000 % Change From 5 Years Low (%) +79.39
Change From 5 Years High -2475.000 % Change From 5 Years High (%) -67.81
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

PT Phapros Tbk is a pharmaceutical company, which is engaged in the production and marketing of pharmaceutical products. The firm's segments include OTC (Over The Counter), Toll-in, Ethical and OGB (generic drugs bearing). The company was founded on June 21, 1954 and is headquartered in Jakarta, Indonesia.

Historical Price Data

Date Open High Low Close Volume VWAP
27 Jul 2021 1185.000 1195.000 1170.000 1175.000 492,300 1179.8273
26 Jul 2021 1180.000 1200.000 1180.000 1185.000 179,700 1184.4630
23 Jul 2021 1190.000 1210.000 1180.000 1190.000 224,700 1191.7623
22 Jul 2021 1195.000 1205.000 1190.000 1190.000 357,800 1197.6859
21 Jul 2021 1190.000 1190.000 1170.000 1180.000 184,100 1178.2048
19 Jul 2021 1180.000 1190.000 1170.000 1190.000 241,900 1181.0356
16 Jul 2021 1195.000 1220.000 1195.000 1195.000 315,200 1200.0476
15 Jul 2021 1260.000 1280.000 1195.000 1195.000 1,422,100 1225.6445
14 Jul 2021 1180.000 1335.000 1175.000 1255.000 5,777,300 1254.3489
13 Jul 2021 1220.000 1220.000 1180.000 1180.000 195,400 1189.5061
12 Jul 2021 1180.000 1275.000 1170.000 1220.000 790,800 1227.8996
09 Jul 2021 1200.000 1200.000 1165.000 1170.000 433,500 1174.3702
08 Jul 2021 1245.000 1245.000 1160.000 1190.000 631,500 1198.2795
07 Jul 2021 1205.000 1235.000 1200.000 1210.000 219,500 1212.7175
06 Jul 2021 1265.000 1265.000 1200.000 1205.000 789,400 1217.6469
05 Jul 2021 1220.000 1300.000 1215.000 1260.000 1,309,000 1253.8552
02 Jul 2021 1225.000 1235.000 1205.000 1210.000 811,300 1216.5524
01 Jul 2021 1180.000 1230.000 1170.000 1205.000 1,431,000 1204.2180
30 Jun 2021 1180.000 1190.000 1160.000 1165.000 453,800 1170.7294
29 Jun 2021 1235.000 1280.000 1175.000 1180.000 1,251,100 1205.2318
28 Jun 2021 1190.000 1270.000 1170.000 1230.000 2,125,300 1211.0850
25 Jun 2021 1150.000 1300.000 1150.000 1160.000 1,975,100 1214.1400
Summary
Current 2 Weeks
(13 Jul 2021 to 27 Jul 2021)
1220.000 1335.000 1170.000 1175.000 9,390,500 -
Previous 2 Weeks
(29 Jun 2021 to 12 Jul 2021)
1235.000 1335.000 1170.000 1220.000 8,120,900 -
4 Weeks from
(31 May 2021 to 28 Jun 2021)
1220.000 1335.000 1170.000 1230.000 30,723,100 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.